National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.


NCPE Assessment Process Complete
Rapid review commissioned 10/09/2018
Rapid review completed 18/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care.